<DOC>
	<DOCNO>NCT00099437</DOCNO>
	<brief_summary>The purpose study evaluate efficacy new dose 500 mg Fulvestrant standard dose 250 mg postmenopausal woman oestrogen receptor positive advance breast cancer fail previous endocrine treatment .</brief_summary>
	<brief_title>Comparison Fulvestrant ( FASLODEXâ„¢ ) 250 mg 500 mg Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing Relapsing After Previous Endocrine Therapy .</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>Breast Cancer continue grow receive treatment antiestrogen hormonal treatment tamoxifen aromatase inhibitor Requiring hormonal treatment Postmenopausal woman define woman stop menstrual period Evidence positive estrogen receptor hormone sensitivity Written inform consent participate trial Treatment investigational nonapproved drug within one month An exist serious disease , illness , condition prevent participation compliance study procedures A history allergy active inactive ingredient Faslodex ( i.e . castor oil ) Treatment one regimen chemotherapy advance breast cancer Treatment one regimen hormonal treatment advance breast cancer</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Advanced Breast Cancer</keyword>
	<keyword>Metastatic Breast Cancer</keyword>
</DOC>